Cargando…
Clinical outcomes of patients with metachronous second primary lung adenocarcinomas
BACKGROUND: The incidence of adenocarcinomas as multiple primary lung cancers (MPLCs) is increasing. How to determine the treatment strategies of MPLCs, especially second primary lung adenocarcinomas (SPLACs), and the prognostic factors associated with it are unclear. METHODS: The clinical records o...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237587/ https://www.ncbi.nlm.nih.gov/pubmed/28138252 http://dx.doi.org/10.2147/OTT.S122908 |
_version_ | 1782495555675488256 |
---|---|
author | Zhao, Heng Yang, Haitang Han, Ke Xu, Jianlin Yao, Feng Zhao, Yang Fan, Liwen Gu, Haiyong Shen, Zhenya |
author_facet | Zhao, Heng Yang, Haitang Han, Ke Xu, Jianlin Yao, Feng Zhao, Yang Fan, Liwen Gu, Haiyong Shen, Zhenya |
author_sort | Zhao, Heng |
collection | PubMed |
description | BACKGROUND: The incidence of adenocarcinomas as multiple primary lung cancers (MPLCs) is increasing. How to determine the treatment strategies of MPLCs, especially second primary lung adenocarcinomas (SPLACs), and the prognostic factors associated with it are unclear. METHODS: The clinical records of patients undergoing surgery for second adenocarcinomas based on Martini–Melamed criteria between 2001 and 2014 were retrospectively reviewed. Survival rates were calculated by the Kaplan–Meier method and compared using the log-rank test. Multivariate analysis was conducted using the Cox proportional hazards model. RESULTS: A total of 115 patients with SPLACs were identified based on Martini–Melamed criteria. With respect to the second resections, three subgroups with low- (adenocarcinoma in situ, n=6; minimally invasive adenocarcinoma, n=19), intermediate- (lepidic, n=9; acinar, n=40; papillary, n=23), and high-grades (solid, n=9; micropapillary, n=2; invasive mucinous, n=7) were assigned. The 5-year overall survival (OS) rates from the time of the first and the second resections were 86.5% and 69.5%, respectively. Cox multivariate analysis identified computed tomography (CT) morphology of SPLACs (ground glass opacity predominant versus solid predominant; hazard ratio [HR]=0.42; P=0.036), histologic classification (same/similar vs different; HR=0.06; P<0.001), pathologic stage of the primary (stage I vs II; HR=0.20; P=0.015) and second tumors (stage I vs IIIa; HR=0.21; P=0.002), and histologic grade of SPLACs (low- vs high-grade, HR=0.05, P=0.016; intermediate- vs high-grade, HR=0.37, P=0.027) as significantly favorable prognostic factors for OS. CONCLUSION: In addition to pathologic stage of the initial tumors and histologic classification, pathologic stage and CT morphology of SPLACs were identified as predictors of survival. The histologic grade of SPLACs based on the new adenocarcinoma classification could provide additional prognostic information. |
format | Online Article Text |
id | pubmed-5237587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-52375872017-01-30 Clinical outcomes of patients with metachronous second primary lung adenocarcinomas Zhao, Heng Yang, Haitang Han, Ke Xu, Jianlin Yao, Feng Zhao, Yang Fan, Liwen Gu, Haiyong Shen, Zhenya Onco Targets Ther Original Research BACKGROUND: The incidence of adenocarcinomas as multiple primary lung cancers (MPLCs) is increasing. How to determine the treatment strategies of MPLCs, especially second primary lung adenocarcinomas (SPLACs), and the prognostic factors associated with it are unclear. METHODS: The clinical records of patients undergoing surgery for second adenocarcinomas based on Martini–Melamed criteria between 2001 and 2014 were retrospectively reviewed. Survival rates were calculated by the Kaplan–Meier method and compared using the log-rank test. Multivariate analysis was conducted using the Cox proportional hazards model. RESULTS: A total of 115 patients with SPLACs were identified based on Martini–Melamed criteria. With respect to the second resections, three subgroups with low- (adenocarcinoma in situ, n=6; minimally invasive adenocarcinoma, n=19), intermediate- (lepidic, n=9; acinar, n=40; papillary, n=23), and high-grades (solid, n=9; micropapillary, n=2; invasive mucinous, n=7) were assigned. The 5-year overall survival (OS) rates from the time of the first and the second resections were 86.5% and 69.5%, respectively. Cox multivariate analysis identified computed tomography (CT) morphology of SPLACs (ground glass opacity predominant versus solid predominant; hazard ratio [HR]=0.42; P=0.036), histologic classification (same/similar vs different; HR=0.06; P<0.001), pathologic stage of the primary (stage I vs II; HR=0.20; P=0.015) and second tumors (stage I vs IIIa; HR=0.21; P=0.002), and histologic grade of SPLACs (low- vs high-grade, HR=0.05, P=0.016; intermediate- vs high-grade, HR=0.37, P=0.027) as significantly favorable prognostic factors for OS. CONCLUSION: In addition to pathologic stage of the initial tumors and histologic classification, pathologic stage and CT morphology of SPLACs were identified as predictors of survival. The histologic grade of SPLACs based on the new adenocarcinoma classification could provide additional prognostic information. Dove Medical Press 2017-01-10 /pmc/articles/PMC5237587/ /pubmed/28138252 http://dx.doi.org/10.2147/OTT.S122908 Text en © 2017 Zhao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zhao, Heng Yang, Haitang Han, Ke Xu, Jianlin Yao, Feng Zhao, Yang Fan, Liwen Gu, Haiyong Shen, Zhenya Clinical outcomes of patients with metachronous second primary lung adenocarcinomas |
title | Clinical outcomes of patients with metachronous second primary lung adenocarcinomas |
title_full | Clinical outcomes of patients with metachronous second primary lung adenocarcinomas |
title_fullStr | Clinical outcomes of patients with metachronous second primary lung adenocarcinomas |
title_full_unstemmed | Clinical outcomes of patients with metachronous second primary lung adenocarcinomas |
title_short | Clinical outcomes of patients with metachronous second primary lung adenocarcinomas |
title_sort | clinical outcomes of patients with metachronous second primary lung adenocarcinomas |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237587/ https://www.ncbi.nlm.nih.gov/pubmed/28138252 http://dx.doi.org/10.2147/OTT.S122908 |
work_keys_str_mv | AT zhaoheng clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas AT yanghaitang clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas AT hanke clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas AT xujianlin clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas AT yaofeng clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas AT zhaoyang clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas AT fanliwen clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas AT guhaiyong clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas AT shenzhenya clinicaloutcomesofpatientswithmetachronoussecondprimarylungadenocarcinomas |